D. T. Dudley

发表

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

A. Doherty, J. Warmus, A. Bridges, 2008, Bioorganic & medicinal chemistry letters.

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2004, Nature Structural &Molecular Biology.

A synthetic inhibitor of the mitogen-activated protein kinase cascade.

A. Bridges, A. Saltiel, S. Decker, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Alan R. Saltiel, A. Bridges, W. Leopold, 1999, Nature Medicine.

Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases.

D. T. Dudley, J. Reiners, M. Guo, 2001, Biochemical pharmacology.

Effect of Modificationof PlasmaMembraneFatty Acid Compositionon Fluidityand MethotrexateTransport in L 1210 Murine Leukemia Cells 1

A. A. Spector, D. T. Dudley, G. Buettner, 2006 .

Butyrate effects on normal and adapted hepatoma cells: morphological response and implications for vectoral cholesterol transport.

R. Chalkley, P. Wright, D. T. Dudley, 1986, Archives of biochemistry and biophysics.

Comparative utilization of n-3 polyunsaturated fatty acids by cultured human Y-79 retinoblastoma cells.

A. A. Spector, D. T. Dudley, M. Yorek, 1984, Biochimica et biophysica acta.

Analysis of the role of N-glycosylation in cell-surface expression and binding properties of angiotensin II type-2 receptor of rat pheochromocytoma cells.

G. Servant, D. T. Dudley, E. Escher, 1996, The Biochemical journal.

Overview: Recent Advances in Angiotensin II Receptor Antagonists

J. M. Hamby, D. T. Dudley, J. Hamby, 1993 .

Subclasses of angiotensin II binding sites and their functional significance.

R. Panek, G. Lu, T. Major, 1990, Molecular pharmacology.

Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinaseγ

D. T. Dudley, M. Liimatta, K. Para, 2007 .

Corrigendum: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

J. Warmus, J. Sebolt-Leopold, Chunhong Yan, 2005, Nature Structural &Molecular Biology.

A Pharmacological Approach to the MAP Kinase Cascade

A. Saltiel, D. T. Dudley, 2000 .

Depletion of arachidonic acid from GH3 cells. Effects on inositol phospholipid turnover and cellular activation.

A. A. Spector, D. T. Dudley, D. Macfarlane, 1987, The Biochemical journal.

Characterization of angiotensin II (AT2) binding sites in R3T3 cells.

D. T. Dudley, S. Hubbell, R. Summerfelt, 1991, Molecular pharmacology.

Effect of modification of plasma membrane fatty acid composition on fluidity and methotrexate transport in L1210 murine leukemia cells.

A. A. Spector, D. T. Dudley, G. Buettner, 1979, Cancer research.

Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells

D. T. Dudley, R. Summerfelt, 1993, Regulatory Peptides.

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*)

Philip R. Cohen, D. Alessi, A. Saltiel, 1995, The Journal of Biological Chemistry.

Phospholipid activation of the insulin receptor kinase: regulation by phosphatidylinositol

J. Pessin, A. A. Spector, D. T. Dudley, 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.

A. Doherty, D. T. Dudley, W. L. Cody, 1993, Journal of medicinal chemistry.

The marked disparity between the sizes of angiotensin type 2 receptors from different tissues is related to different degrees of N-glycosylation.

G. Servant, D. T. Dudley, E. Escher, 1994, Molecular pharmacology.

Structure-activity relationships in a series of monocyclic endothelin analogues

A. Doherty, D. T. Dudley, W. L. Cody, 1994 .

Amylin increases cyclic AMP formation in L6 myocytes through calcitonin gene-related peptide receptors.

A. Saltiel, D. T. Dudley, G. Zhu, 1991, Biochemical and biophysical research communications.

The Role of Arachidonic Acid in the Secretion of the Amyloid Precursor Protein (APP) a

R. D. Dyer, R. T. Carroll, M. Emmerling, 1996, Annals of the New York Academy of Sciences.

Novel Muscarinic Agonists for the Treatment of Alzheimer’s Disease

D. T. Dudley, H. Tecle, W. Moos, 1991 .

Inositol phospholipid arachidonic acid metabolism in GH3 pituitary cells.

A. A. Spector, D. T. Dudley, A. Spector, 1986, The Biochemical journal.

Mechanistic and pharmacological characterization of PF-04457845 : a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain

Shobha N. Bhattachar, D. Nomura, B. Cravatt, 2011 .

Analysis of rat amylin amide from commercial sources: Identification of a mercury complex.

M. Reily, D. T. Dudley, W. L. Cody, 1991 .

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

Benjamin F. Cravatt, Paul Wren, Shobha N. Bhattachar, 2011, Journal of Pharmacology and Experimental Therapeutics.

Design of a functional hexapeptide antagonist of endothelin.

A. Doherty, R. Panek, T. Major, 1992, Journal of medicinal chemistry.

Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease

D. T. Dudley, H. Tecle, J. Jaén, 1993 .

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Shobha N. Bhattachar, B. Cravatt, D. T. Dudley, 2011, ACS medicinal chemistry letters.

Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352

E. Fauman, D. T. Dudley, Amy M. Delaney, 2002, Molecular and Cellular Biology.

PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase.

D. T. Dudley, J. Reiners, S. Myrand, 1998, Molecular pharmacology.

A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies

S. Weiss, Xiao-yan Li, C. Kleer, 2014, Proceedings of the National Academy of Sciences.

Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.

S. Barrett, D. T. Dudley, H. Tecle, 2007, Arthritis and rheumatism.

Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice

B. Cravatt, A. Lichtman, S. Kinsey, 2011, Pharmacology Biochemistry and Behavior.

The utilization of ethanolamine and serine for ethanolamine phosphoglyceride synthesis by human Y79 retinoblastoma cells.

D. T. Dudley, M. Yorek, A. Spector, 1985, The Journal of biological chemistry.

Temperature dependence and effect of membrane lipid alteration on melphalan transport in L1210 murine leukemia cells.

D. T. Dudley, C. Burns, 1982, Biochemical pharmacology.

Biopterin. VI. Purification and primary amino acid sequence of mammalian D-erythro-7,8-dihydroneopterin triphosphate synthetase.

D. T. Dudley, A. Sherman, E. Gal, 1979, Neurochemical Research.

Fatty acid alteration of L1210 murine leukemia cells. Growth rate and stability of lipid changes in culture.

D. T. Dudley, C. Burns, D. G. Luttenegger, 1980, Journal of the National Cancer Institute.

Functional differences in insulin receptors in rat adipocyte and human placenta membranes.

M. Swanson, J. Pessin, D. T. Dudley, 1988, Endocrinology.

Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.

D. T. Dudley, H. Tecle, J. Jaén, 1993, Progress in brain research.